Status:

COMPLETED

Effect of High volumeHemodiafiltration on Lung Oxygenation

Lead Sponsor:

Assiut University

Conditions:

Haemofiltration

Lung Mechanics

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

High volume hemodiafiltration (HVHDF) has been used in septic patients to get hemodynamic improvement and possibly survival benefit.

Detailed Description

Sepsis, defined as life-threatening organ dysfunction caused by dysregulated immune response to infection. Hemofiltration has been suggested as beneficial in restoring immune homeostasis. High volume ...

Eligibility Criteria

Inclusion

  • ≥ 18 years
  • Severe sepsis defined by Quick SOFA score by presentation of 2 or more of the following criteria:
  • Mental clouding: decreased glasco coma scale GCS \< 15
  • Hypotension: Systolic blood pressure \< 100 mmgH
  • Tachypnea: respiratory rate \> 22 breath/ minute Then serum lactate is analysed to confirm sepsis hypoperfusion if ≥ 2mmol/L
  • Organs dysfunction (including one of them respiratory failure).
  • Organ dysfunctions are defined as following:
  • Respiratory dysfunction (criteria for ARDS):
  • PaO2/FiO2 \<200
  • Bilateral infiltrates in chest X-ray
  • Resistant hypoxemia
  • Tachypnoea (RR \> 40 breath/minute)
  • The need for invasive mechanical ventilation
  • Excluded cardiac causes of pulmonary edema
  • CNS failure:
  • Decreased GCS ≥ 4 decreased points
  • CVS dysfunction:
  • Sustained hypotension even on very high inotropes doses (Noradrenaline \>1µm/min)+ adrenaline\>1.5µm/min associated
  • with high CVP pressure \> 12 mmHg and not responding to fluid challenge test to exclude hypovolemia.
  • Cardiomegaly detected by either echocardiography assessment, or chest X-ray
  • Resistant frequent ventricular ectopics not explained by organic causes.
  • Liver dysfunction:
  • Elevated total and direct bilirubin than double normal or basal levels
  • Elevated prothrombin time \> 17 seconds or INR \> 1.5
  • Elevated liver enzymes \> triple normal level
  • Renal dysfunction:
  • Decreased urine output \< 0.5 ml/kg.
  • Elevated creatinine level \> 164 µmol/L (1.5mg/dL).
  • Decreased creatinine clearance \<50ml/minute if available.
  • Bone marrow depression:
  • Decreased platelets \< 90 X 103/µL
  • Decreased leukocytes \<4 X 103/µL
  • Decreased RBCs count \< 4 X 106/µL

Exclusion

  • Patient relatives' refusal
  • Pregnancy
  • Recent active internal hemorrhage
  • Not mechanically ventilated.
  • Hypersensitivity to the dialyser fluid

Key Trial Info

Start Date :

March 20 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 10 2020

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT03853005

Start Date

March 20 2019

End Date

November 10 2020

Last Update

August 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Faculty of medicine - Assiut university

Asyut, Egypt